<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00116285</url>
  </required_header>
  <id_info>
    <org_study_id>RagweedMATAMPL101</org_study_id>
    <secondary_id>P1DP05003</secondary_id>
    <nct_id>NCT00116285</nct_id>
  </id_info>
  <brief_title>Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing</brief_title>
  <official_title>A Single-Blind Phase I Study to Assess the Residual Allergenicity of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL Using Skin Prick Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergy Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergy Therapeutics</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the residual allergenicity of the modified ragweed
      pollen in Ragweed MATA MPL (modified pollen allergen tyrosine adsorbate + Monophosphoryl
      Lipid A) by skin prick testing. This is done by a comparison of the wheal response after skin
      prick testing with different concentrations of aqueous native allergen, modified allergen,
      modified tyrosine adsorbed allergen, and Ragweed MATA MPL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ragweed MATA MPL has been developed to provide pre-seasonal specific immunotherapy for
      patients with proven type I hypersensitivity to ragweed pollen. MPL (Monophosphoryl Lipid A),
      a purified, detoxified glycolipid derived from the cell wall of Salmonella minnesota, is
      included in the product formulation as an adjuvant to increase the immunogenic effect of the
      product and to enhance the switch from an allergen-specific TH2 to a TH1-like profile.

      The ragweed pollen extract is modified with glutaraldehyde to produce the active ingredient,
      an allergoid. This modification reduces the reactivity of the extract with IgE antibody, thus
      reducing the risk of side effects. However, a simultaneous reduction in other important
      immunological properties, such as IgG and T cell reactivities is not seen.

      The purpose of this study is to assess residual allergenicity of the modified ragweed pollen
      in Ragweed MATA MPL using skin prick testing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date>June 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the allergenicity of the modified ragweed pollen in Ragweed MATA MPL compared to unmodified native allergen using skin prick testing</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of the skin prick test products</measure>
  </secondary_outcome>
  <enrollment>12</enrollment>
  <condition>Type I Hypersensitivity</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ragweed MATA MPL</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  If the volunteer is female of childbearing potential, she must demonstrate a negative
             urine pregnancy test and agree to remain abstinent or use an effective method of birth
             control

          -  Positive skin prick test to ragweed pollen allergen extract

          -  Positive skin prick test to positive histamine control

          -  Negative skin prick test to negative control; redness, but no wheal is acceptable

          -  The subject must demonstrate a specific IgE for ragweed with class &gt;= 2.

          -  The subject must have clinically acceptable results from the screening procedure
             including blood pressure (BP), heart rate (HR), electrocardiogram (ECG), physical
             examination, medical history, hematology, biochemistry, infection screen (hepatitis B
             antigen, hepatitis C antibody, HIV), urine pregnancy test, urinalysis, drugs of abuse
             screening panel and saliva alcohol testing

        Exclusion Criteria:

          -  History or presence of acute or subacute atopic dermatitis, chronic dermatitis,
             urticaria factitia, or urticaria due to physical/chemical influence or any other skin
             conditions which might interfere with the interpretation of skin prick test results

          -  Visual inspection of the forearms indicates potential problems with the conduct or
             interpretation of the skin prick tests; both forearms must be available for testing

          -  Subject has asthma or other lower respiratory tract condition

          -  History or presence of diabetes, cancer or any clinically significant cardiac,
             metabolic, renal, hepatic, gastrointestinal, dermatologic, venereal, hematologic,
             neurologic or psychiatric diseases or disorders

          -  Any clinically significant abnormal laboratory value at Visit 1

          -  Clinically relevant sensitivity to any of the following common perennial or seasonal
             allergens: house dust mites, molds, epithelia, grass pollen mix, plantain, orache,
             nettle, mugwort, bermuda grass

          -  Clinically relevant symptoms due to an IgE-mediated allergy at screening and before
             inclusion to the treatment period

          -  Secondary alteration at the affected organ

          -  History of auto-immune diseases or rheumatoid diseases

          -  Medical condition that prohibits the use of adrenaline

          -  Disorder of tyrosine metabolism

          -  Diseases interfering with the immune response and having received medication which
             could influence the results of this study

          -  Subject has acute or chronic infection

          -  History of anaphylaxis

          -  Subjects determined by the Investigator to have any medical condition that could
             jeopardize their health or prejudice the results

          -  History of hypersensitivity to the excipients of the study medication

          -  History of immunotherapy with ragweed allergen extracts

          -  Current therapy with ÃŸ-blockers

          -  Currently receiving anti-allergy medication or other drugs with an antihistaminic
             activity

          -  Subject has a positive drugs of abuse screen at Visit 1

          -  Subject participated in a clinical trial and has taken investigational drug within the
             last 30 days

          -  Subject cannot communicate reliably with the Investigator or is deemed uncooperative
             or noncompliant

          -  Females who are pregnant, breastfeeding, or refuse to use a reliable method of birth
             control

          -  Subject received treatment with a preparation containing MPL during the past 12 months

          -  Use of prohibited medications or inadequate washout periods prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepen Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allied Research International Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allied Research International Inc.</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2005</study_first_submitted>
  <study_first_submitted_qc>June 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2005</study_first_posted>
  <last_update_submitted>June 16, 2010</last_update_submitted>
  <last_update_submitted_qc>June 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2010</last_update_posted>
  <keyword>allergy</keyword>
  <keyword>skin prick test</keyword>
  <keyword>allergoid</keyword>
  <keyword>allergenicity</keyword>
  <keyword>specific immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Hypersensitivity, Immediate</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Monophosphoryl lipid A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

